" class="no-js "lang="en-US"> Hemispherian Raises First Tranche of Series A to Fund the Development of its Novel Cancer Therapeutics - Medtech Alert
Friday, June 14, 2024

Hemispherian Raises First Tranche of Series A to Fund the Development of its Novel Cancer Therapeutics

Hemispherian AS, a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce the closure of the first tranche of its series A1 funding round. The round raised NOK 30M (USD 2.9M). The proceeds will support the company’s drug development activities, expand its preclinical pipeline and advance its lead therapeutic compounds towards clinical development.

The Hemispherian funding round was led by the Dutch Investment Firm, Meneldor, who partnered with Norwegian and American investors. Among the Norwegian investors are Kistefos AS and Kvantia AS. Most of the earlier investors followed their seed investment, and the board chaired by Steven Powell, remains unchanged.

“Hemispherian continues to accelerate its clinical ambitions and we are pleased to continue our support of Hemispherian’s selective anti-cancer pharmaceutical pipeline. This funding will support preclinical development of GLIX1 and GLIX5, the company’s lead assets,” says Paul Lelieveld, Meneldor Co-Founder.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more